Catalent Pharma Solutions has made organizational changes within its biologics business following the 2017 acquisition of Cook Pharmica and its 875,000 square-foot facility in Bloomington, IN.

Tedd Green, former President of Cook Pharmica, becomes senior vice president of Catalent Biologics, and will have responsibility for the entire biologics business. He will continue to report to Barry Littlejohns, president, Catalent Biologics and Specialty Drug Delivery, and will also act as a member of Catalent’s executive leadership team. Mr. Green will be based at the Bloomington facility.

Mike Riley becomes vice president and general manager of drug substance and bioanalytical services for Catalent Biologics. He will lead the company’s biologics manufacturing business, including its state-of-the-art mammalian cell-line engineering and biomanufacturing capabilities, and its broad bioanalytical capabilities based at several sites across Catalent’s global network.

Cory Lewis will take on the new role of vice president and general manager of the Catalent Biologics Drug Product business, with a focus on successfully growing the Catalent Biologics drug product offerings both in the U.S. and in Europe.

Lastly, Ryan Hawkins has been appointed as general manager of the Bloomington site, having been instrumental to its success through his contributions and leadership over the last ten years.